NCT06546436View on ClinicalTrials.gov

The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

November 15, 2025

Study Completion Date

May 31, 2027

Conditions

Autoimmune Type 1 Diabetes Mellitus(T1DM)

Interventions

DRUG

CARC-101C

Subjects enrolled in the project will received a one-dose injection of CARC-101C

Trial Locations (1)

210008

Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University, Nanjing

Sponsors

Collaborators (1)

Carcell Biopharma Ltd.

All Listed Sponsors

collaborator

Carcell Biopharma Ltd.

UNKNOWN

lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER